Acceleron Pharma, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (21)

Latest Posts

About This Stock More About This Stock
Acceleron Downgraded To Neutral From Overweight At Piper Jaffray
Article By: The Fly
Tuesday, July 10, 2018 7:19 AM EST
Piper Jaffray analyst Edward Tenthoff downgraded Acceleron Pharma to Neutral and lowered his price target for the shares to $52 from $55.
In this article: XLRN Also: CELG
Read
Biotechnology Stocks Preparing A New Bullish Trend
Article By: Taki Tsaklanos
Sunday, July 8, 2018 11:26 AM EST
Biotechnology stocks look bullish, and even more bullish than ever in the last three years.
In this article: IBB, ILMN, REGN, BIIB, CELG, XBI, ARRY, FOLD, SGMO, XLRN
Read
On The Fly: Top Stock Stories For Friday, June 29, 2018
Article By: The Fly
Friday, June 29, 2018 11:49 PM EST
Stocks opened in positive territory after taking their cue from European and Asian markets, which traded higher overnight. Here is a brief roundup of notable economic events, company news and the major movers of the week.
In this article: DB, GS, MS, NKE, CVG, SNX, GM, STZ, THC, CELG, XLRN, GEMP
Read
JPMorgan Upgrades Acceleron To Overweight Ahead Of Luspatercept Data
Article By: The Fly
Monday, February 26, 2018 9:07 AM EST
JPMorgan analyst Eric Joseph upgraded Acceleron Pharma to Overweight from Neutral and raised his price target for the shares to $52 from $33 ahead of pivotal data for lead asset luspatercept in myelodysplastic syndrome and beta-thalassemia.
In this article: XLRN
Read
Celgene Potentially Worth $200 Per Share, Says Analyst
Article By: The Fly
Monday, July 10, 2017 8:44 PM EST
Shares of biotech giant Celgene may be worth $200 per share if peak sales of late-stage assets, including luspatercept, ozanimod, and GED301 are met, said analyst Ying Huang.
In this article: CELG, XLRN
Read

PARTNER HEADLINES

Latest Tweets for $XLRN

No tweets yet!